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Mutation pattern is an influential factor 
on functional mutation rates in cancer
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Abstract 
Background: Mutation rates are consistently varied in cancer genome and play an important role in tumorigenesis, 
however, little has been known about their function potential and impact on the distribution of functional mutations. 
In this study, we investigated genomic features which affect mutation pattern and the function importance of muta-
tion pattern in cancer.
Methods: Somatic mutations of clear-cell renal cell carcinoma, liver cancer, lung cancer and melanoma and single 
nucleotide polymorphisms (SNPs) were intersected with 54 distinct genomic features. Somatic mutation and SNP 
densities were then computed for each feature type. We constructed 2856 1-Mb windows, in which each row (1-Mb 
window) contains somatic mutation, SNP densities and 54 feature vectors. Correlation analyses were conducted 
between somatic mutation, SNP densities and each feature vector. We also built two random forest models, namely 
somatic mutation model (CSM) and SNP model to predict somatic mutation and SNP densities on a 1-Kb scale. The 
relation of CSM and SNP scores was further analyzed with the distributions of deleterious coding variants predicted by 
SIFT and Mutation Assessor, non-coding functional variants evaluated with FunSeq 2 and GWAVA and disease-causing 
variants from HGMD and ClinVar databases.
Results: We observed a wide range of genomic features which affect local mutation rates, such as replication time, 
transcription levels, histone marks and regulatory elements. Repressive histone marks, replication time and promoter 
contributed most to the CSM models, while, recombination rate and chromatin organizations were most important 
for the SNP model. We showed low mutated regions preferentially have higher densities of deleterious coding muta-
tions, higher average scores of non-coding variants, higher fraction of functional regions and higher enrichment of 
disease-causing variants as compared to high mutated regions.
Conclusions: Somatic mutation densities vary largely across cancer genome, mutation frequency is a major indica-
tion of function and influence on the distribution of functional mutations in cancer.
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Background
Cancer is a malignant disease as the result of the accu-
mulation of somatic mutations (base pair substitutions, 
insertions, deletions, rearrangements and copy num-
ber changes) and the disruption of functions of criti-
cal genes and pathways in normal cells. Over the past 
10 years, the rapid development and wide application of 
sequencing technology have enabled a full detection of 
somatic mutations in cancer genome. The big projects, 
such as The Cancer Genome Atlas and International 
Cancer Genome Consortium projects, have sequenced 
more than 25 thousand cancer genomes and exomes and 
provided tremendous mutation data, which facilitates 
a broad evaluation of mutation patterns and their roles 
in cancer initiation and development [1, 2]. Studies have 
consistently shown that somatic mutation rates are not 
constant across cancer genome and a variety of genomic 
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properties influence local mutation densities, for 
instance, mutation frequency is increased close to break-
points of structural rearrangements [3]. Mutagenesis is 
also highly affected by genomic features such as replica-
tion timing [4, 5], transcription levels [6] and chromatin 
organizations [7] in various cancer types.
It’s well accepted that somatic mutations play a piv-
otal role in carcinogenesis, however the extent to which 
mutation frequency affects cancer formation and devel-
opment isn’t completely understood. For example, tumor 
cells with enhanced mutation frequency are prone to 
accumulation of driver mutations that confer a growth 
advantage to tumor cells and therefore are likely to 
develop cancer [8]. Hypermutated cancer genome pos-
sesses the prevalent signatures in genes which are criti-
cal to cancer initiation and progression [9, 10]. Moreover, 
recurrently mutated genes in a cohort of patients are 
regarded as cancer-driving genes under positive selection 
in cancers [6, 11]. However, few studies have been con-
ducted on the function potential of mutation spectrum 
and its relation with functional somatic mutations in 
cancer. In this study, we characterized mutation patterns 
of four cancer types, including ccRCC, liver cancer, lung 
adenocarcinoma and melanoma. We observed a wide 
range of genomic features which affect local mutation 
rates and showed the importance of mutation frequency 
with respect to functionalities of somatic mutations. Low 
mutated regions have higher densities of deleterious 
mutations, higher average scores of non-coding variants, 
higher fraction of functional regions, and higher enrich-
ment of disease-causing variants from HGMD and Clin-
Var databases than high mutated regions, supporting that 
mutation frequency is an important indicator of function 
and exerts a great impact on the distribution of func-
tional mutations in cancer genome.
Results
The somatic mutation profile in cancer
To investigate the mutation pattern and what fac-
tors influence mutation rates in cancers, we obtained 
71,424 somatic mutations from 14 paired ccRCC and 
normal samples [12], 2,011,261 variants from 25 mela-
noma patients [13], 1,845,976 from 24 lung adenocarci-
noma patients, and 881,136 from 88 liver cancer patients 
[6] (see “Methods” section). We also took 38,248,779 
SNPs (single nucleotide polymorphism) from the 1000 
genomes project pilot one [14] as a comparison. We 
intersected somatic mutations and SNPs with a wide 
range of genomic features, epigenetic properties and 
computed the average mutation densities of somatic 
mutations and SNPs for each feature type. Figure 1 and 
Additional file 1: Figure S1–S4 showed the somatic muta-
tion and SNP densities associated to various features. We 
found functionally important regions, such as CDS, pro-
moter, UTR and ncExons are relatively low mutated com-
pared to introns of lncRNAs (P value <0.05 in most cases 
Fig. 1 Densities of cancer somatic mutations of ccRCC associated to a wide range of genomic features chromosome by chromosome. For each 
chromosome, the size of each feature was calculated and numbers of somatic mutations were counted, somatic mutation densities were com-
puted. The red and blue dashed lines stand for CDS and genome-wide average mutation densities. CDS coding sequence, CR conserved region, ECS 
evolutionarily conserved structure, GCH and GCL 1 Kb-windows with high and low GC content, Exon.P and Exon.L, Intron.P and Intron.P exon and 
intron of protein coding gene and lncRNA respectively, PCgene protein coding gene, cTFBS conserved TFBS, UTR Untranslated region, PCgene.ER and 
PCgene.LR, LncRNA.ER and LncRNA.LR early and late replicated protein coding gene and lncRNA, PCgene.HE and PCgene.LE, LncRNA.HE and LncRNA.
LE high and low expressed protein coding gene and lncRNA, RRH and RRL 1 Kb-windows with high and low recombination rate, H3K4me1, H3K9ac, 
etc. histone methylation and acetylation data, ncExon non coding Exon
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except for promoter in kidney cancer and ncExon in 
melanoma and CDS, UTR for SNPs, Wilcoxon rank sum 
test). Furthermore, we obtained 5 cancer driver genes in 
ccRCC, VHL, PBRM1, TCEB1, BAP1 and SETD2, from 
Sato’s study [12], we found only two mutations, one in 
the CDS and another in the promoter of PBRM1, sug-
gesting the CDS, promoters and UTR of these cancer-
driving genes are mainly protected from mutations in 
ccRCC. Exons of either protein coding genes or lncR-
NAs showed lower somatic mutation rates relative to 
their introns respectively (P value <0.05 for lncRNAs in 
all cases, P value <0.05 for protein coding genes in liver 
and lung cancer, Wilcoxon rank sum test). However, no 
significant difference was observed on the SNP den-
sity between exons and introns of either protein coding 
genes or lncRNAs (P value  >0.05 in all cases, Wilcoxon 
rank sum test). Expression level and replication time are 
two important factors affecting cancer mutation and 
SNP rates, as evidenced by consistently lower mutation 
and SNP rates in high expressed and early replicated 
genes versus low expressed and late replicated ones (P 
value <0.05 in all cases with a range from 0.008 to 2.429e-
13, Wilcoxon rank sum test). Repressive histone marks, 
such as H3K9me1, H3K9me2, H3K9me3, H3K27me2 
and H3K27me3 are largely over-mutated in comparison 
with active histone marks, such as H3K4me1, H3K4me2, 
H3K79me1,H3K79me2,H3K79me3, and H4K20me1 (P 
values range from 0.3482 to 2.429e-13 and are less than 
0.05 in 95.83 % of cases for cancer somatic mutations, P 
values range from 0.8618 to 3.5742e-09 and are less than 
0.05 in 73.33  % of cases for SNPs, Wilcoxon rank sum 
test). Furthermore, in order to further characterize the 
relation between somatic mutation, SNP rates and each 
feature, we constructed 2856 1-Mb windows, in which 
each row (1-Mb window) contains somatic mutation, 
SNP densities and 54 feature vectors (see “Methods” 
section). Correlation analyses were conducted between 
cancer somatic mutation, SNP densities and each feature 
vector. Features such as promoter, replication time, CDS, 
UTR are most negatively correlated with both somatic 
mutation and SNP densities (r  =  −0.3036 to −0.6178, 
P value <1.5233e-61 for somatic mutations; r = −0.0264 
to −0.1219, P value = 1.6048e-01–7.2937e-11 for SNPs). 
Repressive histone marks, such as H3K9me1, H3K9me2, 
H3K9me3, H4K20me3, H3K27me2 show high positive 
correlations with both somatic mutation and SNP densi-
ties (r = 0.1336–0.6044, P value <1.1440e-12 for somatic 
mutations; r  =  0.3393–0.5178, P value  =  0 for SNPs) 
(Fig.  2). In general, SNP rates exhibit a large difference 
with somatic mutations, such as conserved regions and 
cTFBS (conserved transcription factor binding sites). 
These two regions are over-mutated in somatic muta-
tions but protected from SNPs (Fig.  1). Recombination 
rates show strong positive correlation with SNPs but 
Fig. 2 Correlation coefficients of cancer somatic mutation (CSM), SNP densities with diverse genetic and epigenetic features at 1-Mb resolution
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a relatively weak correlation with somatic mutations 
(r  =  −0.1210–0.0499, P value  <7.8871e-03 for somatic 
mutations; r  =  0.5015, P value  =  0 for SNPs). Moreo-
ver, multiple features have contrasting correlations 
with somatic mutation and SNP rates, such as H3K4ac, 
H4K5ac, H3K4me1, H3K4me2, H4K20me1 and ncExon 
(Fig. 2), suggesting distinct mutation patterns of somatic 
mutations and SNPs in cancer genome.
Cancer somatic mutation (CSM) and SNP random forest 
models
Given the sparse number of cancer mutations, we built 
two random forest models, referred to as the CSM and 
SNP models, with 2856 1-Mb windows constructed 
above in order to analyze mutation distribution in more 
detail. %IncMSE is computed from permuting a predic-
tor’s values over the original dataset, if a predictor is 
important in the model, the prediction error on the out-
of-bag portion of the data (MSE for regression) will be 
increased [15]. We used %IncMSE to measure feature 
importance in the random Forest. In the CSM model, 
repressive histone marks such as H3K9me1, H3K9me2, 
H3K27me3, H3K27me2 and H4K20me3, replication time 
and promoter are among the most informative factors, 
which corresponds to the findings in the correlation anal-
yses (Fig. 3a; Additional file 1: Figure S5). However, fea-
tures such as CDS, UTR have medium importance in the 
CSM model, a possible explanation is these regions are 
relatively small in the genome and have little impact on 
genome-wide mutation rates, supporting that repressive 
histone marks, replication time and promoter contribute 
most to the CSM models. In the SNP model, the most 
important features are recombination rate, H4R3me2, 
H4K20me3, ECS, H3R3me2 and H3K27me2, which is in 
line with the correlation analyses above (Fig. 3b).
Functionality and mutation frequency
Next, we asked whether mutation frequencies are asso-
ciated to functionality and distribution of functional 
mutations. In order to examine this hypothesis, firstly, 
we constructed annotation data which are overlapping 
1-Mb windows with a step size 1  Kb using all 54 fea-
tures, CSM and SNP densities (CSM and SNP scores) 
were predicted with the CSM and SNP random models 
for each 1  Mb-window and cancer type and averaged 
on a 1  Kb scale (see “Methods” section). We applied 
SIFT and Mutation Assessor to predict damaging cod-
ing mutations for all cancer types. In total, 10,572, 
1208,1625, 2519, and 7745, 1924,3009,3579 mutations 
were predicted as deleterious by SIFT and Mutation 
Assessor in ccRCC, liver cancer, lung cancer and mela-
noma respectively. We found markedly higher densi-
ties of deleterious mutations in the low CSM and SNP 
scoring regions as compared with those in the high 
CSM and SNP scoring ones. Moreover, negative corre-
lations of average CSM and SNP scores were observed 
with densities of damaging mutations (r = −0.6034 to 
−0.9060 for CSM scores, r = −0.4721 for SNP scores, p 
value  <0.05 in all cases), suggesting strong enrichment 
of deleterious mutations in the low mutated regions 
(Fig.  4a, b; Additional file  1: Figure S6). On the other 
hand, we computed functional scores for all non-coding 
mutations with FunSeq 2 and GWAVA and analyzed 
their distributions with respect to mutation rates. We 
observed that hypomutated regions with low CSM and 
SNP scores have higher average FunSeq 2 and GWAVA 
scores than hypermutated ones. Take the 200 Mb inter-
vals with the highest and lowest CSM and SNP scores as 
examples, the 200 Mb interval with the lowest average 
CSM score has higher average GWAVA and FunSeq 2 
scores than that with highest CSM score (P value <2.2e-
16 in all cases, Wilcoxon rank sum test); The differences 
of average GWAVA and FunSeq 2 scores are relatively 
weak between the 200  Mb intervals with lowest SNP 
score and highest SNP score (P value  =  0.0090 for 
GWAVA, P value = 0.161 for FunSeq 2, Wilcoxon rank 
sum test) (Fig.  4c, d; Additional file  1: Figure S7). Fur-
thermore, we took 100  Mb lowest and highest scoring 
CSM, SNP regions respectively and analyzed their dis-
tributions across various genetic features. As expected, 
functionally important regions, such as CDS, exons, 
UTR, splicing sites of protein coding genes and miR-
NAs, have 2–48-fold higher enrichment of low CSM 
and SNP scoring regions than high CSM and SNP scor-
ing regions (P value <2.2e-16 for all cases, Chi squared 
test), however, nearly functionally neutral regions, such 
as lncRNAs and intron of lncRNAs are 1.5–2-fold more 
enriched with high CSM and SNP scoring regions rela-
tive to low CSM and SNP scoring ones (P value <2.2e-
16 for all cases, Chi squared test). Strikingly, fractions of 
low CSM and SNP scoring regions are 7~ times higher 
than those of high CSM and SNP scoring regions in 
cancer-related miRNAs and genes (P value <2.2e-16 in 
all cases, Chi squared test) (Fig.  5a; Additional file  1: 
Figure S8). In addition, ccRCC driver genes, VHL, 
PBRM1, TCEB1, BAP1 and SETD2, are all located in 
the low scoring 1-Kb windows, their average CSM 
scores are 21.436, 20.7088, 25.043, 20.7625 and 20.3447 
respectively, which are less than the average (25.0582) in 
ccRCC. Lastly, we obtained non-coding disease-causing 
variants from HGMD and ClinVar databases and ana-
lyzed their distributions with regards to mutation rates. 
Disease-associated variants have lower average SNP and 
CSM scores than random SNPs (P value  <2.2e-16 in 
all cases, Wilcoxon rank sum test) (Fig.  5b; Additional 
file  1: Figure S9). Low CSM and SNP scoring regions 
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have higher enrichment of disease-causing variants 
than high CSM and SNP scoring ones. Take the lowest 
and highest CSM and SNP scoring 200-Mb intervals as 
examples, the former has an 14–117 times higher aver-
age densities of disease-causing variants than the latter 
(P value  <2.2e-16 in all cases, Chi squared test). Sig-
nificant negative correlations were observed between 
average CSM and SNP scores and densities of disease-
associated variants (r  =  −0.6593 to −0.7790 for CSM 
scores,−0.5718 for SNP scores, P values  <0.05 in all 
cases) (Fig.  5c, d; Additional file  1: Figure S10). All 
these findings support the fact that mutation rate is an 
important indicator of function and an influential fac-
tor on the distribution of functional mutations in cancer 
genome.
Discussion
In this study, we have characterized the mutation spec-
trum in four cancer types and observed a wide range 
of genomic features that contribute to somatic muta-
tion variations across cancer genome. The most influ-
ential features are replication time, transcription levels, 
repressive, active histone marks and regulatory ele-
ments. In line with many studies [4–6, 16], we found 
late replicated genes are more mutable as compared to 
early replicated ones, the mechanisms underlying this 
phenomenon might be explained in two ways. First of 
all, exhaustion of dNTP in the late stages of DNA rep-
lication might cause increase of single strand DNA 
regions which are more susceptible to mutagenesis [17, 
18]; Secondly, mutation repair systems might erode 
Fig. 3 Importance measured by %IncMSE for each feature in the CSM and SNP RF models a %IncMSE importance of all features in the CSM RF 
model; b  %IncMSE importance of all features in the SNP RF model
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in the late replicated genes, leading to lack of efficient 
repair of mutation lesions [4]. Another feature associ-
ated with elevated mutation rate is low expressed genes. 
High transcription might reduce number of mutations 
through transcription-coupled repair (TCR), which 
would repair more DNA lesions along with global 
genome repair (GGR) than GGR could operate alone in 
low transcribed regions [19]. TCR also in part accounts 
for mutation frequency variations among repressive, 
active histone marks, exons, CDS, UTR and introns. 
Regions, such as repressive condensed chromatin and 
introns, are subject to increased mutation rates, which 
could be due to more active TCR in highly transcribed 
open chromatin, CDS, UTR and exons. Regulatory ele-
ments like promoters show reduced local densities 
of somatic mutations, probably due to the integrity of 
nucleotide excision repair pathway consisting of global 
genome repair and TCR, which guarantees the efficient 
removal of mutation lesions [20]. Lastly, we found that 
recombination rates positively correlate with somatic 
mutation and SNP densities, which is in agreement with 
Lercher’s study [21] ⁠but contrasts with that obtained by 
Renjamin’s study [7]. In particular, recombination rates 
are a major influential factor on the SNP density, which 
is mostly attributed to mutagenesis of recombination 
rate and faulty repair of the double-strand breaks that 
initiate recombination [21]. Consistent with mutation 
pattern in cancers, we found that repressive histone 
marks, promoter and replication time contribute most 
to the CSM models, features like recombination rate 
Fig. 4 The impact of CSM and SNP scores on the distribution of deleterious coding variants and functional non-coding variants. a average CSM 
scores correlate negatively with densities of deleterious coding variants predicted by SIFT and Mutation Assessor on a 200 Mb scale; b average SNP 
scores correlate negatively with densities of deleterious coding variants predicted by SIFT and Mutation Assessor on a 200 Mb scale; c The distribu-
tion of FunSeq 2 and GWAVA scores for non-coding variants with regards to CSM scores; d The distribution of FunSeq 2 and GWAVA scores for 
non-coding variants with regards to SNP scores
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and chromatin organizations are most important for the 
SNP model.
Next, we asked whether mutation rate variations are a 
byproduct of mutation repair systems or represent can-
cer mutation selection and function in cancer. Here we 
showed mutation frequencies are linked to the distribu-
tion of functional mutations in cancers. Low mutated 
regions tend to enrich functional mutations, including 
deleterious coding mutations, functional non-coding 
mutations and disease-causing mutations, suggesting 
their importance in the formation of functionalities of 
somatic mutations. Another evidence that further sup-
port this idea is low mutated regions possess strikingly 
higher enrichment of functional regions, such as CDS, 
exons, UTR, splicing sites of protein coding genes, 
cancer-related miRNAs and cancer driver genes as 
compared to high mutated regions, which explains why 
low mutated regions are prone to form functional muta-
tions. Currently, many studies prefer to emphasize the 
importance of hypermutation in cancer initiation and 
development [8, 19], and hypermutation is an indicator 
of positive selection in cancer genes and multiple com-
putational methods have been developed to detect them 
[6, 11, 22]. Our study show that hypomutated regions are 
mutation constraints and associated to functions in can-
cer genome, which should draw more attention and work 
in the future.
Conclusions
Taken together, somatic mutation densities vary largely 
across cancer genome, replication time, transcription 
levels, chromatin modifications and regulatory elements 
Fig. 5 The impact of CSM and SNP scores on the distribution of disease-causing variants from the ClinVar and HGMD databases. a The average 
fraction of 100 Mb low CSM, SNP, high CSM and SNP scoring regions in various features; b The distribution of CSM and SNP scores for ClinVar, HGMD 
disease-causing variants and random SNPs, random SNPs are 1 % SNPs randomly chosen from 1000 human genomes project; c The correlation of 
average CSM scores with densities of disease-causing variants on a 200 Mb scale; d The correlation of average SNP scores with densities of ClinVar, 
and HGMD disease-causing variants on a 200 Mb scale
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are among the features which most affect local mutation 
rates. To a large extent, mutation frequency is an indi-
cation of function and influence on the distribution of 
functional mutations in cancer.
Methods
Mutation data
Somatic variants were generated by whole genome 
sequencing of paired cancer and normal tissues and 
obtained from three studies: 2,011,261 variants from 
25 melanoma patients [13], 1,845,976 variants from 24 
lung adenocarcinoma patients, and 881,136 variants 
from 88 liver cancer patients [6] and 71,424 variants 
from 14 paired ccRCC and normal samples [12].Variants 
described as “substitution” or “indel” were both collected 
and are referred to collectively as mutations in the text. 
Germ line mutation data including 38,248,779 SNPs (sin-
gle nucleotide polymorphism) were obtained from the 
1000 genomes project [14] ⁠ (http://www.1000genomes.
org). Disease-associated variants data come from ClinVar 
(Version 2014/03/03, 55,689 variants) [23] and HGMD 
[24] (Version 2014/04/14, 166,768 variants) databases 
which are two common curations of variants related to 
human inherited diseases, coding variants were removed 
in this study, forming 6045 and 13,108 disease-implicated 
variants in the non-coding genome.
Genome‑wide data resources
Human genome annotation were obtained from Gen-
code V21, including protein coding genes, exons, introns, 
UTR, non-coding exons (ncExon) ect [25]. Evolutionar-
ily conserved bases with phast Cons score greater than 
117 were identified through alignment of 46 mamma-
lian genomes with human [26]. Evolutionarily conserved 
structures (ECS) are RNA secondary structures pre-
dicted with a nouvel pipeline based on RNAz and SIS-
SIz in Smith MA’ study [27]. Promoters generated by 
the Gerstein lab are regulatory regions 2.5 Kb from tran-
scription start sites (TSS) [28]. Genome-wide mapping 
of histone acetylation and methylation data of CD4+  T 
cell line were produced by ChIP-seq in Wang’s [29] and 
Barski’s study [30] respectively, all coordinates conver-
sion from hg18 assembly to hg19 was performed with the 
UCSC Lift Over program [26]. Conserved TFBS (con-
served transcription factor binding sites, cTFBS) were 
generated through aligning mouse and rat genomes with 
human [31]. Replication time data were obtained from 
Hepg2, Imr90, K562 and Bg02 cell lines for liver cancer, 
lung cancer, ccRCC and melanoma respectively (http://
genome.ucsc.edu/) ENCODE, ‘Repli-seq track’ [31]. 
Genome-wide replication timing was mapped to protein 
coding genes and lncRNAs, the (G1b  +  S1)/(S4  +  G2) 
ratio, early-to-late ratio, was determined for each protein 
coding gene and lncRNA. Genes that have a ratio greater 
than 1 or less than 1 were defined as early or late repli-
cated genes respectively. Recombination rates (RR) were 
obtained from International HapMap Project (http://
hapmap.ncbi.nlm.nih.gov/) and averaged over successive 
1-Kb windows in human genome [32]. 1-Kb windows 
that have an average RR above 4.0 were regarded as high 
RR regions (RRH), while low RR regions are 1-Kb win-
dows with recombination rate less than 0.5 (RRL). GC 
content denotes the percentage of G or C nucleotides per 
1-Kb window. 1-Kb windows that have greater than 50 % 
or less than 30  % GC coverage are considered as high 
(GCH) or low GC regions (GCL) respectively [26].
RNA-seq data in sra format generated by sequenc-
ing 6 Hek293T cell lines were downloaded from NCBI 
(GSE55572) [33] for expression analysis in ccRCC. Read 
alignment was conducted with TopHat2 release 2.0.13 
[34]. As for other cancer types, RNA-seq data in bam 
format were acquired from Hepg2, A549 and Nhek cell 
lines for liver cancer, lung cancer and melanoma respec-
tively [31]. Read coverage was determined with bedtools 
v2.22.1 for lncRNAs and protein coding genes [35]. The 
number of reads per Kilobase per million reads (RPKM) 
was computed and averaged from three cell samples for 
each protein coding gene and lncRNA. Genes whose 
RPKM  >20 or  <0.25 were defined as high and low 
expressed respectively.
Cancer micro RNAs are a manual curation of mamma-
lian miRNAs that have been experimentally character-
ized and actively involved in various cancers [36]. Cancer 
census genes are 547 cancer-driving genes annotated in 
COSMIC v71 (catalogue of somatic mutations in cancer) 
[37].
Construction of 1‑Mb windows and correlation analyses
We used 1-Mb window strategy to construct 1-Mb 
windows for correlation analyses between SNP, cancer 
somatic mutation densities and genetic features as well 
as fitting Random forest models. Non-overlapping 1-Mb 
windows were formed across human genome, cancer 
mutations and SNPs were mapped into them and the 
number of somatic mutations and SNPs were counted 
for each 1-Mb window. Genome-wide replication tim-
ing was mapped into 1-Mb windows and the (G1b+S1)/
(S4+G2) ratio was computed for each 1-Mb window. 
Read coverage was determined with bedtools v2.22.1 
for each 1-Mb window, exons from Gencode V21 were 
intersected with 1-Mb windows and the length of exons 
was then calculated for each 1-Mb window. The num-
ber of reads per Kilobase per million reads (RPKM) was 
computed and averaged from three cell samples for each 
1-Mb window. Recombination rates (RR) were averaged 
over successive 1-Mb windows in the human genome. 
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Regarding other features, the number of bases covered by 
each feature was calculated for each 1-Mb window. As a 
number of 1-Mb windows are lack of coverage of features 
and mutation information, partial 1-Mb windows were 
discarded, including 1-Mb windows defined as telomere, 
centromere, stalk, pericentromere, 1-Mb windows which 
are all undefined bases. The whole chromosome Y was 
ruled out from this study too, due to its consistently low 
mutation rates caused by gender bias. In total, 224.3 Mb 
regions were abandoned in this study, forming 2856 
1-Mb windows and 56 columns corresponding to cancer 
somatic mutation density, SNP density and 54 features 
ranging from conserved regions, promoters to histone 
modifications. Correlation analyses between SNP, cancer 
somatic mutation densities and each feature were per-
formed in R.
Random forest model
The SNP and cancer somatic mutation (CSM) random 
forest (RF) models were constructed with the R random 
Forest package [15]. In the RF models, we used 2856 
1-Mb windows constructed above and cancer muta-
tion density (CSM model), SNP density (SNP model) as 
response variables and 54 genomic features as predictor 
variables to build two RF models, CSM and SNP mod-
els. All predictor values were plus one and log scaled to 
reduce the great variation of vectors. The number of trees 
was set to 500, mtry was set to 20 for CSM model and 15 
for SNP model, all other parameters were set to default 
values. Model calibration and validation were described 
in the Additional file 2.
For CSM and SNP score prediction, we used the same 
1-Mb window strategy as in the model building, however, 
the 1 Mb-window was slided across the human genome 
with a step size of 1 Kb. 1 Mb windows overlapping tel-
omere, centromere, stalk or pericentromere regions, 
1 Mb windows which are all undefined bases and chro-
mosome Y were removed from the annotation data, 
resulting in 2,832,687 row annotations. The CSM and 
SNP scores were predicted using the two RF models for 
each 1 Mb window and averaged on a 1-Kb window scale.
Correlation analyses between CSM, SNP scores 
and deleterious coding mutations, GWAVA and FunSeq 2 
non‑coding scores, disease‑causing variants
Coding mutations mainly came from two sources for 
ccRCC: whole genome sequencing of 14 paired ccRCC 
samples and exome sequencing of 325 paired ccRCC 
samples from TCGA [38]. The coding mutations of other 
cancer types were obtained from the same sources as 
described in the section of “Mutation data”. Their func-
tional impacts were predicted by SIFT [39], and Mutation 
assessor [40] respectively, variants were regarded as dele-
terious based on the following criteria: SIFT score <0.05, 
and Mutation Assessor socre  >1.9. 70,659 ccRCC, 
881,130 liver cancer, 1,623,242 lung cancer and 2,011,261 
melanoma non-coding variants were scored with Fun-
Seq 2 [41] (http://funseq2.gersteinlab.org/) and GWAVA 
[42] (https://www.sanger.ac.uk/sanger/StatGen_Gwava) 
respectively, all the parameters were set to default. Del-
eterious coding mutations, non-coding variants with 
GWAVA and FunSeq 2 scores and disease-causing vari-
ants from HGMD and ClinVar databases were mapped 
into 1-Kb windows which have average CSM and SNP 
scores. 1-Kb windows were then sorted based on SNP 
and CSM scores and divided into non-overlapping 200-
Mb intervals respectively. For each 200-Mb interval, the 
following values were computed, including the aver-
age densities of deleterious coding mutations, disease-
causing variants, average GWAVA and FunSeq 2 scores, 
average CSM and SNP scores. Correlation analyses were 
conducted in R between densities of deleterious coding 
mutations, disease-causing variants and average CSM 
and SNP scores.
Statistical analyses
Data were presented as mean, statistical differences 
between groups were computed with the Chi squared 
test (chisq.test) or Wilcoxon rank sum test (wilcox.
test), correlation analysis (cor.test) was conducted in R, 
P < 0.05 was regarded statistically significant and the null 
hypothesis was rejected.
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